EMA — authorised 23 August 2022
- Marketing authorisation holder: JANSSEN-CILAG INTERNATIONAL N.V.
- Status: approved
🇪🇺 Bcmaxcd3 in European Union
EMA authorised Bcmaxcd3 on 23 August 2022
Marketing authorisation
Bcmaxcd3 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Bcmaxcd3 approved in European Union?
Yes. EMA authorised it on 23 August 2022.
Who is the marketing authorisation holder for Bcmaxcd3 in European Union?
JANSSEN-CILAG INTERNATIONAL N.V. holds the EU marketing authorisation.